Pruvonertinib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, mutant-selective, third-generation epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, pruvonertinib targets, binds to and inhibits the activity of EGFR with exon 20 insertion (Ex20ins) activating mutations, the gatekeeper mutation T790M and some other rare mutations, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.

**Synonyms:** - EGFR Inhibitor YK-029A - EGFR Mutant-selective Inhibitor YK-029A - EGFR TKI YK-029A - Mutant-selective EGFR Inhibitor YK-029A - PRUVONERTINIB - YK 029A - YK-029A - YK029A